Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Open Monoclonal Technology
Builds the first platform for generating human monoclonal antibodies using a transgenic rat
Palo Alto, CA
Contact:
Ron Eastman
Acquired by: Ligand Pharmaceuticals
Exit date: December 11, 2015
Related News
Open Monoclonal Technology Announces OmniAb Alliance with Celgene
OMT Announces New Antibody Discovery Program
Open Monoclonal Technology Provides Important Intellectual Property Update
Cambridge Healthtech Associates™ Announces Open Monoclonal Technology as Inaugural Signature Award™
